|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM355256762 |
| 003 |
DE-627 |
| 005 |
20250304151459.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.37616/2212-5043.1327
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1183.xml
|
| 035 |
|
|
|a (DE-627)NLM355256762
|
| 035 |
|
|
|a (NLM)37020973
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Albabtain, Monirah A
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Better Survival in Morbidly Obese Patients with Atrial Fibrillation Treated with Non-vitamin K-dependent Oral Anticoagulants
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 07.04.2023
|
| 500 |
|
|
|a published: Electronic-eCollection
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a © 2023 Saudi Heart Association.
|
| 520 |
|
|
|a Background: The efficacy and safety of non-vitamin K-dependent anticoagulants (NOAC) are not well investigated in the obese population, and fixed dosing could lead to under-anticoagulation. Our objective was to evaluate the effect of obesity on anticoagulation outcomes and survival in non-valvular atrial fibrillation (AF) patients
|
| 520 |
|
|
|a Methods: We enrolled 755 patients who required anticoagulation for AF from 2015 to 2016. We grouped the patients into four groups. Group 1 (n = 297) included patients with BMI< 40 kg/m2 treated with NOACs, Group 2 (n = 358) included patients on warfarin with BMI< 40 kg/m2, Group 3 (n = 57) had patients on NOACs with BMI≥ 40 kg/m2 and Group 4 (n = 43) included patients on warfarin and BMI≥ 40 kg/m2. Study outcomes were the composite endpoint of stroke, bleeding, and survival
|
| 520 |
|
|
|a Results: Competing risk regression showed that stroke and bleeding were not affected by obesity or treatment (SHR: 1.09 (95% CI: 0.79-1.51); P = 0.62). Older age was the predictor of stroke/bleeding (HR:1.03 (95% CI:1.01-1.06); P = 0.02). Predictors of mortality were heart failure (HR:2.23 (95% CI:1.25-3.97); P = 0.007), lower creatinine clearance (HR: 0.98 (95% CI:0.97-0.98): P < 0.001), non-obese patients on warfarin (HR:3.51 (95%CI:1.6-7.7): P = 0.002) and obese patients on warfarin (HR: 6.7 (95% CI:2.51-17.92); P < 0.001)
|
| 520 |
|
|
|a Conclusion: NOACs could have a similar risk profile to warfarin in obese and non-obese patients with non-valvular AF but could have better survival. Larger randomized trials are recommended
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Bleeding
|
| 650 |
|
4 |
|a Mortality
|
| 650 |
|
4 |
|a Non-vitamin K-dependent anticoagulants
|
| 650 |
|
4 |
|a Stroke
|
| 650 |
|
4 |
|a Warfarin
|
| 700 |
1 |
|
|a Alanazi, Zaid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Al Mutairi, Nawaf
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Al Hebaishi, Yahya
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Alyafi, Ola
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Alghasoon, Haneen
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Arafat, Amr A
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of the Saudi Heart Association
|d 1999
|g 35(2023), 1 vom: 21., Seite 7-15
|w (DE-627)NLM098225227
|x 1016-7315
|7 nnas
|
| 773 |
1 |
8 |
|g volume:35
|g year:2023
|g number:1
|g day:21
|g pages:7-15
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.37616/2212-5043.1327
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 35
|j 2023
|e 1
|b 21
|h 7-15
|